IMRN Immuron Limited

6.95
0  0%
Previous Close 6.95
Open
Price To Book 4.89
Market Cap 24883724
Shares 3,580,392
Volume 3
Short Ratio
Av. Daily Volume 1,748

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 commencement of enrollment announced January 31, 2018. Top-line data due 1H 2019.
IMM-529
C. difficile infection
Phase 2 data due 2019.
IMM-124E
Alcoholic steatohepatitis (ASH)
Phase 2 Interim analysis July 10, 2017 showed no statistical difference with placebo. However, company noted March 8, 2018 that top-line data were positive.
IMM-124E
Nonalcoholic steatohepatitis (NASH)
Phase 2 data due late-2019
IMM-124E
Nonalcoholic fatty liver disease (NAFLD) - pediatric